Year Founded
2017
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small molecule

Reactive Biosciences General Information

Company is developing boron-based small molecules targeting historically undruggable targets. Has a PI3K alpha (H1047R mutant) inhibitor program in preclinical development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Reactive Biosciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Reactive Biosciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Reactive Biosciences's complete valuation and funding history, request access »

Reactive Biosciences Investors

Syngenta Group Ventures
Investor Type: Venture Capital
Holding: Minority
Pappas Ventures
Investor Type: Venture Capital
Holding: Minority
Hatteras Venture Partners
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »